The clinical significance of unknown sequence variants in BRCA genes

Cancers

Volumn 2, Issue 3, 2010, Pages 1644-1660

  Calò, Valentina ^a   Bruno, Loredana ^a   la Paglia, Laura ^a   Perez, Marco ^a   Margarese, Naomi ^a   di Gaudio, Francesca ^a   Russo, Antonio ^a  

^a UNIVERSITY OF PALERMO   (Italy)

Author keywords

BRCA genes; Integrated models; Oncogenetic counseling; Variant

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN;

AMINO ACID SUBSTITUTION; BREAST CANCER; CANCER RISK; CLASSIFICATION ALGORITHM; COMPUTER MODEL; GENE DELETION; GENE FREQUENCY; GENE LOCATION; GENE SEGREGATION; GENE SEQUENCE; GENETIC ASSOCIATION; GENETIC CONSERVATION; GENETIC PREDISPOSITION; GENETIC VARIABILITY; HETEROZYGOSITY LOSS; HUMAN; MISSENSE MUTATION; MUTATIONAL ANALYSIS; PROTEIN FUNCTION; PSYCHOLOGICAL ASPECT; REVIEW; RISK ASSESSMENT; SEGREGATION ANALYSIS; SEQUENCE ANALYSIS; UNKNOWN SEQUENCE VARIANT;

EID: 79952284425     PISSN: None     EISSN: 20726694     Source Type: Journal    
DOI: 10.3390/cancers2031644     Document Type: Review

References (65)

1. Miki, Y.; Swensen, J.; Shattuck-Eidens, D.; Futreal, P.A.; Harshman, K.; Tavtigian, S.; Liu, Q.; Cochran, C.; Bennett, L.M.; Ding, W. et al. A strong candidate for the breast and ovarian cancer susceptibility gene brca1. Science 1994, 266, 66-71.
2. Wooster, R.; Bignell, G.; Lancaster, J.; Swift, S.; Seal, S.; Mangion, J.; Collins, N.; Gregory, S.; Gumbs, C.; Micklem, G. Identification of the breast cancer susceptibility gene brca2. Nature 1995, 378, 789-792.
3. Palma, M.; Ristori, E.; Ricevuto, E.; Giannini, G.; Gulino, A. Brca1 and brca2: The genetic testing and the current management options for mutation carriers. Crit. Rev. Oncol. Hematol. 2006, 57, 1-23.
4. Gulati, A.P.; Domchek, S.M. The clinical management of brca1 and brca2 mutation carriers. Curr. Oncol. Rep. 2008, 10, 47-53.
5. Russo, A.; Calo, V.; Agnese, V.; Bruno, L.; Corsale, S.; Augello, C.; Gargano, G.; Barbera, F.; Cascio, S.; Intrivici, C.; Rinaldi, G.; Gulotta, G.; Macaluso, M.; Surmacz, E.; Giordano, A.; Gebbia, N.; Bazan, V. Brca1 genetic testing in 106 breast and ovarian cancer families from southern italy (sicily): A mutation analyses. Breast Cancer Res. Treat. 2007, 105, 267-276.
6. Calo, V.; Agnese, V.; Gargano, G.; Corsale, S.; Gregorio, V.; Cascio, S.; Cammareri, P.; Bruno, L.; Augello, C.; Gullo, A.; Sisto, P.S.; Badalamenti, G.; Valerio, M.R.; Napoli, L.; Gebbia, N.; Bazan, V.; Russo, A. A new germline mutation in brca1 gene in a sicilian family with ovarian cancer. Breast Cancer Res. Treat. 2006, 96, 97-100.
7. King, M.C.; Marks, J.H.; Mandell, J.B. Breast and ovarian cancer risks due to inherited mutations in brca1 and brca2. Science 2003, 302, 643-646.
8. Frank, T.S.; Deffenbaugh, A.M.; Reid, J.E.; Hulick, M.; Ward, B.E.; Lingenfelter, B.; Gumpper, K.L.; Scholl, T.; Tavtigian, S.V.; Pruss, D.R.; Critchfield, G.C. Clinical characteristics of individuals with germline mutations in brca1 and brca2: Analysis of 10,000 individuals. J. Clin. Oncol. 2002, 20, 1480-1490.
9. Easton, D.F.; Deffenbaugh, A.M.; Pruss, D.; Frye, C.; Wenstrup, R.J.; Allen-Brady, K.; Tavtigian, S.V.; Monteiro, A.N.; Iversen, E.S.; Couch, F.J.; Goldgar, D.E. A systematic genetic assessment of 1,433 sequence variants of unknown clinical significance in the brca1 and brca2 breast cancer-predisposition genes. Am. J. Hum. Genet. 2007, 81, 873-883.
10. Augello, C.; Bruno, L.; Bazan, V.; Calo, V.; Agnese, V.; Corsale, S.; Cascio, S.; Gargano, G.; Terrasi, M.; Barbera, F.; Fricano, S.; Adamo, B.; Valerio, M.R.; Colucci, G.; Sumarcz, E.; Russo, A. Y179c, f486l and n550h are brca1 variants that may be associated with breast cancer in a sicilian family: Results of a 5-year goim (gruppo oncologico dell'italia meridionale) prospective study. Ann. Oncol. 2006, 17 (Suppl. 7), 30-33.
11. Goldgar, D.E.; Easton, D.F.; Deffenbaugh, A.M.; Monteiro, A.N.; Tavtigian, S.V.; Couch, F.J. Integrated evaluation of DNA sequence variants of unknown clinical significance: Application to brca1 and brca2. Am. J. Hum. Genet. 2004, 75, 535-544.
12. Chenevix-Trench, G.; Healey, S.; Lakhani, S.; Waring, P.; Cummings, M.; Brinkworth, R.; Deffenbaugh, A.M.; Burbidge, L.A.; Pruss, D.; Judkins, T.; Scholl, T.; Bekessy, A.; Marsh, A.; Lovelock, P.; Wong, M.; Tesoriero, A.; Renard, H.; Southey, M.; Hopper, J.L.; Yannoukakos, K.; Brown, M.; Easton, D.; Tavtigian, S.V.; Goldgar, D.; Spurdle, A.B. Genetic and histopathologic evaluation of brca1 and brca2 DNA sequence variants of unknown clinical significance. Cancer Res. 2006, 66, 2019-2027.
13. Carvalho, M.A.; Marsillac, S.M.; Karchin, R.; Manoukian, S.; Grist, S.; Swaby, R.F.; Urmenyi, T.P.; Rondinelli, E.; Silva, R.; Gayol, L.; Baumbach, L.; Sutphen, R.; Pickard-Brzosowicz, J.L.; Nathanson, K.L.; Sali, A.; Goldgar, D.; Couch, F.J.; Radice, P.; Monteiro, A.N. Determination of cancer risk associated with germ line brca1 missense variants by functional analysis. Cancer Res. 2007, 67, 1494-1501.
14. Couch, F.J.; Rasmussen, L.J.; Hofstra, R.; Monteiro, A.N.; Greenblatt, M.S.; de Wind, N. Assessment of functional effects of unclassified genetic variants. Hum. Mutat. 2008, 29, 1314-1326.
15. Nanda, R.; Schumm, L.P.; Cummings, S.; Fackenthal, J.D.; Sveen, L.; Ademuyiwa, F.; Cobleigh, M.; Esserman, L.; Lindor, N.M.; Neuhausen, S.L.; Olopade, O.I. Genetic testing in an ethnically diverse cohort of high-risk women: A comparative analysis of brca1 and brca2 mutations in american families of european and african ancestry. JAMA 2005, 294, 1925-1933.
16. Weitzel, J.N.; Lagos, V.; Blazer, K.R.; Nelson, R.; Ricker, C.; Herzog, J.; McGuire, C.; Neuhausen, S. Prevalence of brca mutations and founder effect in high-risk hispanic families. Cancer Epidemiol. Biomarkers Prev. 2005, 14, 1666-1671.
17. Judkins, T.; Hendrickson, B.C.; Deffenbaugh, A.M.; Scholl, T. Single nucleotide polymorphisms in clinical genetic testing: The characterization of the clinical significance of genetic variants and their application in clinical research for brca1. Mutat. Res. 2005, 573, 168-179.
18. Farrugia, D.J.; Agarwal, M.K.; Pankratz, V.S.; Deffenbaugh, A.M.; Pruss, D.; Frye, C.; Wadum, L.; Johnson, K.; Mentlick, J.; Tavtigian, S.V.; Goldgar, D.E.; Couch, F.J. Functional assays for classification of brca2 variants of uncertain significance. Cancer Res. 2008, 68, 3523-3531.
19. Goldgar, D.E.; Easton, D.F.; Byrnes, G.B.; Spurdle, A.B.; Iversen, E.S.; Greenblatt, M.S. Genetic evidence and integration of various data sources for classifying uncertain variants into a single model. Hum. Mutat. 2008, 29, 1265-1272.
20. Greenblatt, M.S.; Brody, L.C.; Foulkes, W.D.; Genuardi, M.; Hofstra, R.M.; Olivier, M.; Plon, S.E.; Sijmons, R.H.; Sinilnikova, O.; Spurdle, A.B. Locus-specific databases and recommendations to strengthen their contribution to the classification of variants in cancer susceptibility genes. Hum. Mutat. 2008, 29, 1273-1281.
21. Hofstra, R.M.; Spurdle, A.B.; Eccles, D.; Foulkes, W.D.; de Wind, N.; Hoogerbrugge, N.; Hogervorst, F.B. Tumor characteristics as an analytic tool for classifying genetic variants of uncertain clinical significance. Hum. Mutat. 2008, 29, 1292-1303.
22. Plon, S.E.; Eccles, D.M.; Easton, D.; Foulkes, W.D.; Genuardi, M.; Greenblatt, M.S.; Hogervorst, F.B.; Hoogerbrugge, N.; Spurdle, A.B.; Tavtigian, S.V. Sequence variant classification and reporting: Recommendations for improving the interpretation of cancer susceptibility genetic test results. Hum. Mutat. 2008, 29, 1282-1291.
23. Spurdle, A.B.; Couch, F.J.; Hogervorst, F.B.; Radice, P.; Sinilnikova, O.M. Prediction and assessment of splicing alterations: Implications for clinical testing. Hum. Mutat. 2008, 29, 1304-1313.
24. Tavtigian, S.V.; Greenblatt, M.S.; Lesueur, F.; Byrnes, G.B. In silico analysis of missense substitutions using sequence-alignment based methods. Hum. Mutat. 2008, 29, 1327-1336.
25. Sweet, K.; Senter, L.; Pilarski, R.; Wei, L.; Toland, A.E. Characterization of brca1 ring finger variants of uncertain significance. Breast Cancer Res. Treat. 119, 737-743.
26. Bonatti, F.; Pepe, C.; Tancredi, M.; Lombardi, G.; Aretini, P.; Sensi, E.; Falaschi, E.; Cipollini, G.; Bevilacqua, G.; Caligo, M.A. Rna-based analysis of brca1 and brca2 gene alterations. Cancer Genet. Cytogenet. 2006, 170, 93-101.
27. Ferla, R.; Calo, V.; Cascio, S.; Rinaldi, G.; Badalamenti, G.; Carreca, I.; Surmacz, E.; Colucci, G.; Bazan, V.; Russo, A. Founder mutations in brca1 and brca2 genes. Ann. Oncol. 2007, 18 (Suppl. 6), 93-98.
28. Russo, A.; Calo, V.; Augello, C.; Bruno, L.; Agnese, V.; Schiro, V.; Barbera, F.; Cascio, S.; Foddai, E.; Badalamenti, G.; Intrivici, C.; Cajozzo, M.; Gulotta, G.; Surmacz, E.; Colucci, G.; Gebbia, N.; Bazan, V. 4843delc of the brca1 gene is a possible founder mutation in southern italy (sicily). Ann. Oncol. 2007, 18 (Suppl. 6), 99-102.
29. Russo, A.; Calo, V.; Bruno, L.; Schiro, V.; Agnese, V.; Cascio, S.; Foddai, E.; Fanale, D.; Rizzo, S.; Di Gaudio, F.; Gulotta, E.; Surmacz, E.; Di Fede, G.; Bazan, V. Is brca1-5083del19, identified in breast cancer patients of sicilian origin, a calabrian founder mutation? Breast Cancer Res. Treat. 2009, 113, 67-70.
30. Tang, T.S.; Solomon, L.J.; Yeh, C.J.; Worden, J.K. The role of cultural variables in breast self-examination and cervical cancer screening behavior in young asian women living in the united states. J. Behav. Med. 1999, 22, 419-436.
31. Boyd, J. Brca1: More than a hereditary breast cancer gene? Nat. Genet. 1995, 9, 335-336.
32. Kuschel, B.; Gayther, S.A.; Easton, D.F.; Ponder, B.A.; Pharoah, P.D. Apparent human brca1 knockout caused by mispriming during polymerase chain reaction: Implications for genetic testing. Genes Chromosomes Cancer 2001, 31, 96-98.
33. Tavtigian, S.V.; Samollow, P.B.; de Silva, D.; Thomas, A. An analysis of unclassified missense substitutions in human brca1. Fam. Cancer 2006, 5, 77-88.
34. Judkins, T.; Schwensen, C.; Hendrickson, B.C.; Harpending, H.C.; Barrus, J.; Scholl, T. Automated haplotyping in BRCA1 and localization of polymorphisms on alleles. Am. J. Hum. Genet. 2003, 73, 409.
35. Fleming, M.A.; Potter, J.D.; Ramirez, C.J.; Ostrander, G.K.; Ostrander, E.A. Understanding missense mutations in the brca1 gene: An evolutionary approach. Proc. Natl. Acad. Sci. USA 2003, 100, 1151-1156.
36. Ramirez, C.J.; Fleming, M.A.; Potter, J.D.; Ostrander, G.K.; Ostrander, E.A. Marsupial brca1: Conserved regions in mammals and the potential effect of missense changes. Oncogene 2004, 23, 1780-1788.
37. Abkevich, V.; Zharkikh, A.; Deffenbaugh, A.M.; Frank, D.; Chen, Y.; Shattuck, D.; Skolnick, M.H.; Gutin, A.; Tavtigian, S.V. Analysis of missense variation in human brca1 in the context of interspecific sequence variation. J. Med. Genet. 2004, 41, 492-507.
38. Spearman, A.D.; Sweet, K.; Zhou, X.P.; McLennan, J.; Couch, F.J.; Toland, A.E. Clinically applicable models to characterize brca1 and brca2 variants of uncertain significance. J. Clin. Oncol. 2008, 26, 5393-5400.
39. Grantham, R. Amino acid difference formula to help explain protein evolution. Science 1974, 185, 862-864.
40. Osorio, A.; de la Hoya, M.; Rodriguez-Lopez, R.; Martinez-Ramirez, A.; Cazorla, A.; Granizo, J.J.; Esteller, M.; Rivas, C.; Caldes, T.; Benitez, J. Loss of heterozygosity analysis at the brca loci in tumor samples from patients with familial breast cancer. Int. J. Cancer 2002, 99, 305-309.
41. Osorio, A.; Milne, R.L.; Honrado, E.; Barroso, A.; Diez, O.; Salazar, R.; de la Hoya, M.; Vega, A.; Benitez, J. Classification of missense variants of unknown significance in brca1 based on clinical and tumor information. Hum. Mutat. 2007, 28, 477-485.
42. Brzovic, P.S.; Keeffe, J.R.; Nishikawa, H.; Miyamoto, K.; Fox, D., 3rd; Fukuda, M.; Ohta, T.; Klevit, R. Binding and recognition in the assembly of an active brca1/bard1 ubiquitin-ligase complex. Proc. Natl. Acad. Sci. USA 2003, 100, 5646-5651.
43. Reid, L.J.; Shakya, R.; Modi, A.P.; Lokshin, M.; Cheng, J.T.; Jasin, M.; Baer, R.; Ludwig, T. E3 ligase activity of brca1 is not essential for mammalian cell viability or homology-directed repair of double-strand DNA breaks. Proc. Natl. Acad. Sci. USA 2008, 105, 20876-20881.
44. Hashizume, R.; Fukuda, M.; Maeda, I.; Nishikawa, H.; Oyake, D.; Yabuki, Y.; Ogata, H.; Ohta, T. The ring heterodimer brca1-bard1 is a ubiquitin ligase inactivated by a breast cancer-derived mutation. J. Biol. Chem. 2001, 276, 14537-14540.
45. Morris, J.R.; Pangon, L.; Boutell, C.; Katagiri, T.; Keep, N.H.; Solomon, E. Genetic analysis of brca1 ubiquitin ligase activity and its relationship to breast cancer susceptibility. Hum. Mol. Genet. 2006, 15, 599-606.
46. Hayes, F.; Cayanan, C.; Barilla, D.; Monteiro, A.N. Functional assay for brca1: Mutagenesis of the cooh-terminal region reveals critical residues for transcription activation. Cancer Res. 2000, 60, 2411-2418.
47. Phelan, C.M.; Dapic, V.; Tice, B.; Favis, R.; Kwan, E.; Barany, F.; Manoukian, S.; Radice, P.; van der Luijt, R.B.; van Nesselrooij, B.P.; Chenevix-Trench, G.; kConFab; Caldes, T.; de la Hoya, M.; Lindquist, S.; Tavtigian, S.V.; Goldgar, D.; Borg, A.; Narod, S.A.; Monteiro, A.N. Classification of brca1 missense variants of unknown clinical significance. J. Med. Genet. 2005, 42, 138-146.
48. Moynahan, M.E.; Pierce, A.J.; Jasin, M. Brca2 is required for homology-directed repair of chromosomal breaks. Mol. Cell. 2001, 7, 263-272.
49. Wu, K.; Hinson, S.R.; Ohashi, A.; Farrugia, D.; Wendt, P.; Tavtigian, S.V.; Deffenbaugh, A.; Goldgar, D.; Couch, F.J. Functional evaluation and cancer risk assessment of brca2 unclassified variants. Cancer Res. 2005, 65, 417-426.
50. Xia, B.; Sheng, Q.; Nakanishi, K.; Ohashi, A.; Wu, J.; Christ, N.; Liu, X.; Jasin, M.; Couch, F.J.; Livingston, D.M. Control of brca2 cellular and clinical function by a nuclear partner, palb2. Mol. Cell 2006, 22, 719-729.
51. Foulkes, W.D.; Stefansson, I.M.; Chappuis, P.O.; Begin, L.R.; Goffin, J.R.; Wong, N.; Trudel, M.; Akslen, L.A. Germline brca1 mutations and a basal epithelial phenotype in breast cancer. J. Natl. Cancer Inst. 2003, 95, 1482-1485.
52. Turner, N.; Tutt, A.; Ashworth, A. Hallmarks of 'brcaness' in sporadic cancers. Nat. Rev. Cancer 2004, 4, 814-819.
53. Bane, A.L.; Beck, J.C.; Bleiweiss, I.; Buys, S.S.; Catalano, E.; Daly, M.B.; Giles, G.; Godwin, A.K.; Hibshoosh, H.; Hopper, J.L.; John, E.M.; Layfield, L.; Longacre, T.; Miron, A.; Senie, R.; Southey, M.C.; West, D.W.; Whittemore, A.S.; Wu, H.; Andrulis, I.L.; O'Malley, F.P. Brca2 mutation-associated breast cancers exhibit a distinguishing phenotype based on morphology and molecular profiles from tissue microarrays. Am. J. Surg. Pathol. 2007, 31, 121-128.
54. Foulkes, W.D.; Metcalfe, K.; Sun, P.; Hanna, W.M.; Lynch, H.T.; Ghadirian, P.; Tung, N.; Olopade, O.I.; Weber, B.L.; McLennan, J.; Olivotto, I.A.; Begin, L.R.; Narod, S.A. Estrogen receptor status in brca1- and brca2-related breast cancer: The influence of age, grade, and histological type. Clin. Cancer. Res. 2004, 10, 2029-2034.
55. Fitch, W.M. Distinguishing homologous from analogous proteins. Syst. Zool. 1970, 19, 99-113.
56. Vallon-Christersson, J.; Cayanan, C.; Haraldsson, K.; Loman, N.; Bergthorsson, J.T.; Brondum-Nielsen, K.; Gerdes, A.M.; Moller, P.; Kristoffersson, U.; Olsson, H.; Borg, A.; Monteiro, A.N. Functional analysis of brca1 c-terminal missense mutations identified in breast and ovarian cancer families. Hum. Mol. Genet. 2001, 10, 353-360.
57. Capriotti, E.; Arbiza, L.; Casadio, R.; Dopazo, J.; Dopazo, H.; Marti-Renom, M.A. Use of estimated evolutionary strength at the codon level improves the prediction of disease-related protein mutations in humans. Hum. Mutat. 2008, 29, 198-204.
58. Chan, P.A.; Duraisamy, S.; Miller, P.J.; Newell, J.A.; McBride, C.; Bond, J.P.; Raevaara, T.; Ollila, S.; Nystrom, M.; Grimm, A.J.; Christodoulou, J.; Oetting, W.S.; Greenblatt, M.S. Interpreting missense variants: Comparing computational methods in human disease genes cdkn2a, mlh1, msh2, mecp2, and tyrosinase (tyr). Hum. Mutat. 2007, 28, 683-693.
59. Tavtigian, S.V.; Byrnes, G.B.; Goldgar, D.E.; Thomas, A. Classification of rare missense substitutions, using risk surfaces, with genetic- and molecular-epidemiology applications. Hum. Mutat. 2008, 29, 1342-1354.
60. Yang. Likelihood ratio tests for detecting positive selection and application to primate lysozyme evolution. Mol. Biol. Evol. 1998, 15, 568-573.
61. Lakhani, S.R.; Gusterson, B.A.; Jacquemier, J.; Sloane, J.P.; Anderson, T.J.; van de Vijver, M.J.; Venter, D.; Freeman, A.; Antoniou, A.; McGuffog, L.; Smyth, E.; Steel, C.M.; Haites, N.; Scott, R.J.; Goldgar, D.; Neuhausen, S.; Daly, P.A.; Ormiston, W.; McManus, R.; Scherneck, S.; Ponder, B.A.; Futreal, P.A.; Peto, J.; Stoppa-Lyonnet, D.; Bignon, Y.J.; Stratton, M.R. The pathology of familial breast cancer: Histological features of cancers in families not attributable to mutations in brca1 or brca2. Clin. Cancer Res. 2000, 6, 782-789.
62. Lakhani, S.R.; Reis-Filho, J.S.; Fulford, L.; Penault-Llorca, F.; van der Vijver, M.; Parry, S.; Bishop, T.; Benitez, J.; Rivas, C.; Bignon, Y.J.; Chang-Claude, J.; Hamann, U.; Cornelisse, C.J.; Devilee, P.; Beckmann, M.W.; Nestle-Kramling, C.; Daly, P.A.; Haites, N.; Varley, J.; Lalloo, F.; Evans, G.; Maugard, C.; Meijers-Heijboer, H.; Klijn, J.G.; Olah, E.; Gusterson, B.A.; Pilotti, S.; Radice, P.; Scherneck, S.; Sobol, H.; Jacquemier, J.; Wagner, T.; Peto, J.; Stratton, M.R.; McGuffog, L.; Easton, D.F. Prediction of brca1 status in patients with breast cancer using estrogen receptor and basal phenotype. Clin. Cancer Res. 2005, 11, 5175-5180.
63. Roussi, P.; Sherman, K.A.; Miller, S.; Buzaglo, J.; Daly, M.; Taylor, A.; Ross, E.; Godwin, A. Enhanced counselling for women undergoing brca1/2 testing: Impact on knowledge and psychological distress-results from a randomised clinical trial. Psychol. Health 2009, 25, 401-415.
64. Granader, E.J.; Dwamena, B.; Carlos, R.C. Mri and mammography surveillance of women at increased risk for breast cancer: Recommendations using an evidence-based approach. Acad. Radiol. 2008, 15, 1590-1595.
65. Metcalfe, K.A.; Finch, A.; Poll, A.; Horsman, D.; Kim-Sing, C.; Scott, J.; Royer, R.; Sun, P.; Narod, S.A. Breast cancer risks in women with a family history of breast or ovarian cancer who have tested negative for a brca1 or brca2 mutation. Br. J. Cancer 2009, 100, 421-425.